| Sep-2024 | Jun-2024 | Mar-2024 | Dec-2023 | Sep-2023 | |
|---|---|---|---|---|---|
Promoter | - | - | - | - | - |
Foreign | 0% | 0% | 0% | 0% | 0% |
Indian | 41.75% | 41.75% | 41.75% | 41.75% | 41.75% |
Total Promoter | - | - | - | - | - |
Institutions | 1.32% | 1.21% | 1.62% | 1.74% | 1.17% |
Non-Institutions | 56.91% | 57.02% | 56.61% | 56.49% | 57.06% |
Total Non-Promoter | 58.24% | 58.24% | 58.24% | 58.24% | 58.24% |
Custodian | 0% | 0% | 0% | 0% | 0% |
Total | 100% | 100% | 100% | 100% | 100% |
Furthermore, the NPRA's recognition will enable Venus Remedies to capitalise on the expanding global demand for enoxaparin.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
